MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
The current price of MXCT.BOATS is $0.7 USD — it has decreased by -8.36% in the past 24 hours. Watch MaxCyte stock price performance more closely on the chart.
What is MaxCyte stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MaxCyte stocks are traded under the ticker MXCT.BOATS.
What is MaxCyte market cap?▼
Today MaxCyte has the market capitalization of 74.8M
When is the next MaxCyte earnings date?▼
MaxCyte is going to release the next earnings report on May 13, 2026.
What were MaxCyte earnings last quarter?▼
MXCT.BOATS earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.08 USD resulting in a -17.96% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MaxCyte revenue for the last year?▼
MaxCyte revenue for the last year amounts to 77.25M USD.
What is MaxCyte net income for the last year?▼
MXCT.BOATS net income for the last year is -82.11M USD.